All News

Excellent talk by @LCalabreseDO on the balance of the immune response! ⭐️Exhausted T cells seen in rheumatic dz, chronic infections, cancers, severe COVID-19 ⭐️CPI for treatment of latent infections? CPI for treatment of COVID? 🤔 Abs#OP7137 #EULAR2021 @RheumNow https://t.co/18rvFkpPTx

Secukinumab effective in AS patients, irrespective of gender AQUILA 52 week study ⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women ⭐️women had overall higher disease burden in global functioning and depressive mood POS0899 #EULAR2021 @RheumNow

Dr Atienza-Mateo presents abstract #POS0595 on abatacept in RA-ILD. Abatacept surprisingly appeared to be equally good in stabilising FVC and DLCO in both UIP and NSIP patterns in RA-ILD. @RheumNow #EULAR2021 Abstr#POS0595 https://t.co/kHUxWXnaBG

I'm presenting data on COVID-19 in Irish rheumatic disease patients. Age, number comorbidities, glucocorticoids, associated increased hospitalisation. Inflammatory arthritis associated decreased hospitalisation. @RheumNow #EULAR2021 #AbstrPOS1162 https://t.co/0gKxiMNYTf

#EULAR2021 recommendations: RMDs face no more risk of contracting COVID-19, no current evidence of worse prognosis. Do you tell patients similar stats? @RheumNow

#EULAR2021 recommendations on mgmt of RMD in COVID: continue treatment if symptom free, steroids at lowest dose. @Rheumnow. https://t.co/U5zr7EHvTv

Seeing the sites of Paris at virtual #eular2021. Follow on @RheumNow along with @RichardPAConway @MeralElRamahiMD @Yuz6Yusof @Stiddyo @KDAO2011 @uptoTate @AurelieRheumo @drdavidliew @Janetbirdope https://t.co/w18REG08nz

@RheumNow I will be tweeting alongside an amazing team @RichardPAConway @MeralElRamahiMD @Stiddyo @KDAO2011 @uptoTate @Yuz6Yusof @drdavidliew @ejdein1 @Janetbirdope @TammyTilley & last but not least Dr Cush! Follow them and @Rheumnow to stay tuned for the latest science! #EULAR2021

There seem to be quite a few #EULAR2021 abstracts that are identical (or nearly) to #ACR20 abstracts, eg mavrilimumab and GUSTO in vasculitis oral presentation section. Have the rules changed?

Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2 ⭐️sustained DAPSA LDA/remission ⭐️sustained PASDAS LDA/vLDA ⭐️sustained MDA POS1024 #EULAR2021 @RheumNow

C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA ⭐️82% ⬇️ in uveitis flare event ⭐️reduction in axSpA disease activity ⭐️no new safety signals POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY

Longitudinal UK SLE inception cohort 273 pts found: 👉⬆️damage in 1st 3 yrs b/f stabilizing at lower rate 👉mortality uncommon in 1st 12 yrs, but can occur w/in 5 yrs of Dx. 👉unexpected⬆️mortality in Caucasians 38% deaths IHD, 23% infx Abst#0111 #EULAR2021 @rheumnow @Lupusdoc https://t.co/wUwWaB4V2R

Can you predict flares in SLE pts who achieved LLDAS? Retrospec cohort study from Portugal over 3 years of 292 pts who were in LLDAS, 31% flared. Flares seen more in: 👉pts who require ongoing Rx w/ immmunosuppr, GCs 👉pt w/+RNP Abst#0105 #EULAR2021 @RheumNow https://t.co/xfBqGh4pPP

C3 and C4⬆️in SLE pregnancy like they would in pregnancies w/o SLE! French GR2 prospective study of 290 SLE pregnancies quantifies mean C3 value⬆️by 28%, C4⬆️by 11% from 1st ➡️3rd trimester. Remember this when assessing disease activity. #EULAR2021 Abstr #0103 @rheumnow https://t.co/TXjO4mjNJE

Definition of LLDAS: "A state assc w/low likelihood of adverse outcome, considering disease activity and medication safety; it must be favorable, deployable, feasible, and attainable," - Dr. E Morand #EULAR2021 @RheumNow https://t.co/oMMU3AjhmX

Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx

Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk 👉Hormones drive funx change in Treg transciptome 👉anti-inflamm Tregs⬆️in males 👉Tregs are more suppressive in males 👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK

In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weight were negative factors in remission. Abstract #OP0052 #EULAR2021 @RheumNow https://t.co/X4wN1wIGfX https://t.co/DKBIXmEmki

https://ard.bmj.com/content/80/Suppl_1/27.1.full

Female AxSpA pts report worse PROs but have better spinal mobility vs male AxSpA pts. Dz activity pattern similar in 4/6 BASDAI components regardless of gender. Females reports ^ fatigue, males report ^ spinal pain. Abstract# OP0051 #EULAR2021 @RheumNow https://t.co/U8T8JEWwCp https://t.co/yNP6PuA8PD

https://ard.bmj.com/content/80/Suppl_1/27.2

ProDERM study (95 pts): RBPCT phase III IVIG 10% is effective in dermatomyositis (2 g/kg over 2-5 days q4 weeks. (common AEs: HA, fever, nausea most common AEs, rare SAE include thrombosis, LoC, hypoesthesia). Dr. R Aggarwal Abstr#OP008 #EULAR2021 @RheumNow https://t.co/ScTdUySxOl

Topics

All News

Do you get our email newsletter?